Feature | Magnetic Resonance Imaging (MRI) | October 27, 2020

MRI Can Be Safely Performed in Patients With Pacemakers and ICDs

Chest X-ray from a patient included in the study. Posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.

Chest X-ray from a patient included in the study. Posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.

October 27, 2020 – Magnetic resonance imaging (MRI) examinations can be safely performed in patients with non-MR compatible cardiac devices, including pacemakers, abandoned pacing leads, and implantable cardioverter defibrillators (ICDs), according to a new study published in Radiology: Cardiothoracic Imaging.[1]

Millions of people around the world rely on implanted cardiac devices like pacemakers and ICDs to help control abnormal heart rhythms. MRIs are discouraged or prohibited in many of these people over fears that the powerful magnet of the scanner will heat the metal in the devices, potentially damaging heart tissue and harming the devices. 

The U.S. Food and Drug Administration (FDA) has identified a subset of implanted cardiac devices as MR conditional, meaning they pose no known hazard under specified conditions. Pacemakers or ICDs that have not met the criteria are considered non-MR conditional. In these patients, clinicians are forced to choose between removing a necessary cardiac device or getting an alternate and potentially less-effective imaging test.

“While all devices implanted in patients today are MRI compatible, millions of people worldwide, including many young people, have older devices considered not compatible,” said study lead author Sanjaya K. Gupta, M.D., an electrophysiologist from Saint Luke’s Mid America Heart Institute in Kansas City, Mo. “It’s unfair to tell these people that they can’t get an MRI for the rest of their lives.”

Prior research has demonstrated the safety of performing MRI exams in patients with non-MR conditional devices. However, those studies did not account for pacemaker-dependent ICD patients, or patients whose hearts won’t function if the defibrillator is removed or stops working. Other groups not accounted for in previous studies include patients undergoing chest and cardiac MRI exams and patients with abandoned or fractured leads, or wires that connect the device to the heart.

To develop a more comprehensive picture of risk, Gupta and colleagues established the Patient Registry of Magnetic Resonance Imaging in Non-Approved Devices (PROMeNADe). They enrolled more than 500 participants who had undergone a total of 608 MRI exams, including 61 cardiac MRI exams. Participants included people from groups not accounted for in previous research.

Patients had their devices checked before and after each MRI and had their vital signs monitored closely by a nurse during their time in the scanner. Devices were turned to asynchronous mode in pacemaker-dependent patients before they went in the scanner. ICD patients had tachycardia therapies disabled during the MRI.

The results demonstrated that MRI exams—including chest MRI exams—can be performed safely in pacemaker-dependent ICD patients and in patients with non-MR conditional devices or abandoned leads.   

“There were no adverse events,” Gupta explained. “The protocol worked amazingly well. We had no issues with any of the patients and no harm to the devices.”

The registry is now the largest series of MRI scans that has ever been put together in patients with pacemaker-dependent ICDs. It is also the second largest in patients with abandoned or fractured leads and the third largest in non-compatible devices.

Results from a survey of the physicians who had referred the patients for MRI underscored the importance of the exams. According to responses from 150 physicians, MRI results changed the suspected diagnosis 25% of the time and changed suspected prognosis in 26% of participants, with planned medical or surgical treatment being changed 42% of the time.

“We’re hopeful that our work will add support to expand the FDA’s indications for devices that are considered MRI-compatible,” Gupta said.

The study was inspired, in part, by the case of a patient with a brain tumor who was unable to get sorely needed MRI examinations because her pacemaker was not MR conditional. Without MRI results to precisely localize the tumor, the patient had to undergo several risky surgeries.

“A lot of work went into this study but it’s worth it when you consider all the lives impacted,” Gupta said. “I feel like it makes a difference to a lot of people.”

 

Related Content with Dr. Sanjaya Gupta:

VIDEO: Artificial Intelligence to Automatically Risk Stratify Atrial Fibrillation Patients — Interview with Sanjaya Gupta, M.D.

Artificial Intelligence Applications in Cardiology
 

 
Reference:

1. Sanjaya K. Gupta , Lina Ya’qoub, Alan P. Wimmer, Stanley Fisher, Ibrahim M. Saeed. Safety and Clinical Impact of MRI in Patients with Non-MRI-conditional Cardiac Devices. Radiology: Cardiothoracic Imaging. Published Online: Oct 22 2020. https://doi.org/10.1148/ryct.2020200086.

Related Content

1H-MR spectra of 3 consecutive patients with COVID-19. Upper row: Axial FLAIR images at the corona radiata level show representative MRS voxels (black squares) from sampled periventricular regions. Lower row: Corresponding spectrum (black) and LCModel fit (red) from each patient acquired at TE = 30 ms (upper row) and TE = 288 ms (lower row). A, A patient with COVID-19-associated multifocal necrotizing leukoencephalopathy shows diffuse patchy WM lesions with markedly increased Cho and decreased NAA, as well

1H-MR spectra of 3 consecutive patients with COVID-19. Upper row: Axial FLAIR images at the corona radiata level show representative MRS voxels (black squares) from sampled periventricular regions. Lower row: Corresponding spectrum (black) and LCModel fit (red) from each patient acquired at TE = 30 ms (upper row) and TE = 288 ms (lower row). A, A patient with COVID-19-associated multifocal necrotizing leukoencephalopathy shows diffuse patchy WM lesions with markedly increased Cho and decreased NAA, as well as elevated Lac. B, A patient with COVID-19 after recent PEA cardiac arrest with subtle FLAIR hyperintense white matter changes also shows elevated Cho/Cr and decreased NAA/Cr ratios. However, these derangements are less severe than in the patient in A. There is no clear elevation of Lac. C, A patient with COVID-19 without encephalopathy or recent severe hypoxia has normal Cho/Cr, with mildly decreased NAA/Cr and no lactate elevation. Cho, Choline; NAA, N-Acetyl-Aspartate; mI, Myo-Inositol; Lac, Lactate; Glx, Glutamate + Glutamine. Image courtesy of AJNR

News | Coronavirus (COVID-19) | November 19, 2020
November 19, 2020 — One of the first spectroscopic imaging-based studies of neurological injury in...
SyntheticMR, an innovative software solutions company for magnetic resonance imaging (MRI) announced today the company filed a 510(k) submission for its musculoskeletal solutions package, SyMRI MSK.
News | Magnetic Resonance Imaging (MRI) | November 17, 2020
November 17, 2020 — SyntheticMR, an innovative software solutions company for...
Honoring essential healthcareprofessionals, Nov. 8-14
News | Radiology Imaging | November 09, 2020
November 9, 2020 — As COVID-19 continues to spre
This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

Feature | Magnetic Resonance Imaging (MRI) | October 29, 2020
October 29, 2020 — Contrast agents used to improve views of the heart on magnetic resonance imaging (MRI) carry a ver
Vinai Gondi, M.D., the Director of Research at the Northwestern Medicine Chicago Proton Center, Co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

Vinai Gondi, M.D., director of research at the Northwestern Medicine Chicago Proton Center, co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

News | Intensity Modulated Radiation Therapy (IMRT) | October 27, 2020
October 27, 2020 — A...
Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will
This illustration show the complexity of the data obtained from one single patient with moderate/severe traumatic brain injury. Different imaging approaches and techniques have their own unique sensitivity in assessing different aspects of neuroanatomy and neuropathology. What can be seen on images also changes with time since injury. Data from comprehensive clinical and functional assessments using a range of other tools is also important for evaluating patient outcome. Through data harmonization and large

This illustration show the complexity of the data obtained from one single patient with moderate/severe traumatic brain injury. Different imaging approaches and techniques have their own unique sensitivity in assessing different aspects of neuroanatomy and neuropathology. What can be seen on images also changes with time since injury. Data from comprehensive clinical and functional assessments using a range of other tools is also important for evaluating patient outcome. Through data harmonization and large-scale analyses of data combined across multiple research sites, the ENIGMA Brain Injury will develop and test methods and procedures for making sense of the complexity in this data. Images courtesy of Olsen et al., Brain Imaging and Behavior, 2020

News | Magnetic Resonance Imaging (MRI) | October 23, 2020
October 23, 2020 — Trau...
The fMRI hyperscanning environment.

(A) The fMRI hyperscanning environment. The clinician (1) and patient (2) were positioned in two different 3T MRI scanners. An audio-video link enabled online communication between the two scanners (3), and video images were used to extract frame-by-frame facial expression metrics. During simultaneous acquisition of blood oxygen level–dependent (BOLD)–fMRI data, the clinician used a button box (4) to apply electroacupuncture (EA) treatment (real/sham, double-blind) to the patient (5) to alleviate evoked pressure pain to the leg (6; Hokanson cuff inflation). Pain and affect related to the treatment were rated after each trial. (B) Study overview. After an initial behavioral visit, each individual participated in a Clinical-Interaction (hyperscan preceded by a clinical intake) and No-Interaction condition (hyperscan without a preceding intake), in a counterbalanced order, with two different partners. (C) Experimental protocol. Each hyperscan was composed of 12 repeated trials (four verum EA, four sham EA, and four no treatment) in a pseudo-randomized order. After a resting period (far left), both participants were shown a visual cue to indicate whether the next pain stimulus would be treated (green frame) or not treated (red frame) by the clinician. These cues prompted clinicians prepare to either apply or not apply treatment while evoking corresponding anticipation for the patient. Following the anticipation cue, moderately painful pressure pain was applied to the patient’s left leg, while the clinician applied or did not apply treatment, respectively. After another resting period, participants rated pain (patients), vicarious pain (clinicians), and affect (both) using a visual analog scale (VAS).

News | Clinical Trials | October 22, 2020
October 22, 2020 — The potential impact of the patient-clinician relationship on a patient's response to treatment is
The FDA clearance, Quantib’s 6th to date, marks the first time a comprehensive AI prostate solution will be available to radiologists in the United States
News | Prostate Cancer | October 21, 2020
October 21, 2020 — Quantib, a market leader in...